Thursday, April 23, 2026 – Thursday, April 23 - Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks—falling far below analyst and investor expectations.
Thursday, April 23, 2026 – Thursday, April 23 - A new minimally invasive procedure may help people keep weight off after stopping popular drugs like Ozempic and semaglutide—something most patients struggle with. In a clinical trial, those who underwent a technique called duodenal mucosal resurfacing regained far less weight compared to others after discontinuing the medication. The procedure works by renewing the lining of the upper small intestine, potentially “resetting” metabolism and preserving the benefits of weight loss.
Wednesday, April 22, 2026 – Thursday, April 23 - New Life told FDA inspectors that they lacked the authority to enter parts of a facility where it made the GLP-1 receptor agonists semaglutide and tirzepatide.
Wednesday, April 22, 2026 – Thursday, April 23 - Outspoken body acceptance advocate Katie Sturino, who is the founder of Megababe Beauty, explains why it was a difficult decision for her to start taking weight loss drugs. She's joined by psychiatrist Dr. Sue Varma who breaks down what people should do before taking a GLP-1 and the impact of societal pressure.
Wednesday, April 22, 2026 – Thursday, April 23 - Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that would have made GLP-1 drugs more affordable to patients.
Wednesday, April 22, 2026 – Thursday, April 23 - Amazon announced plans to sell the most popular GLP-1 weight loss medications and even offer same-day delivery in the United States. NBC’s Brian Cheung joins TODAY to break down what customers need to know, including whether it will save you money.
Tuesday, April 21, 2026 – Wednesday, April 22 - (MedPage Today) -- A small trial suggested that timing exercise to match body clock chronotype enhanced cardiometabolic and sleep-related outcomes. (Open Heart)
The Society of Thoracic Surgeons published its new guideline for preventing and treating...
Tuesday, April 21, 2026 – Wednesday, April 22 - (MedPage Today) -- Real-world data suggested the dual GLP-1/GIP receptor agonist tirzepatide (Mounjaro, Zepbound) was associated with greater weight loss, but also muscle loss, compared with semaglutide (Ozempic, Wegovy), according to a medical...
Tuesday, April 21, 2026 – Wednesday, April 22 - Natural GLP-1 discovery hidden in joints could revolutionize arthritis treatment...
Monday, April 20, 2026 – Tuesday, April 21 - (MedPage Today) -- Adults whose type 2 diabetes was treated with GLP-1 receptor agonists were more than likely to develop cognitive impairment over 10 years than their counterparts not treated with GLP-1 agents, a propensity-matched retrospective...